Cardiovascular risk factors following orthotopic liver transplantation: Predisposing factors, incidence and management

Liver International

Volumn 30, Issue 7, 2010, Pages 948-957

  Desai, Shireena ^a   Hong, Johnny C ^a   Saab, Sammy ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diabetes; Hyperlipidaemia; Hypertension; Liver transplantation; Obesity

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ATORVASTATIN; BEZAFIBRATE; BISOPROLOL; CALCINEURIN INHIBITOR; CARVEDILOL; CORTICOSTEROID; CYCLOSPORIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; GEMFIBROZIL; GLUCOCORTICOID; INSULIN; LISINOPRIL; MEVINOLIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINIC ACID; NIFEDIPINE; PRAVASTATIN; PREDNISONE; RAMIPRIL; RAPAMYCIN; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TACROLIMUS; TETRAHYDROLIPSTATIN; UNINDEXED DRUG; VERAPAMIL; IMMUNOSUPPRESSIVE AGENT;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; COMPARATIVE STUDY; DIABETES MELLITUS; DISEASE PREDISPOSITION; DRUG DOSE TITRATION; DYSLIPIDEMIA; EDEMA; GRAFT RECIPIENT; GRAFT SURVIVAL; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LUNG GRAFT REJECTION; MYOSITIS; OBESITY; ORTHOTOPIC TRANSPLANTATION; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; SURVIVAL RATE; WEAKNESS; CARDIOVASCULAR DISEASES; MORTALITY; RISK FACTOR; TIME; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LIVER TRANSPLANTATION; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77957143590     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02274.x     Document Type: Review

References (98)

1. Futagawa Y, Terasaki PI, Waki K, Cai J, Gjertson DW. No improvement in long-term liver transplant graft survival in the last decade: an analysis of the UNOS data. Am J Transplant 2006, 6:1398-406.
2. Bianchi G, Marchesini G, Marzocchi R, Pinna AD, Zoli M. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl 2008, 14:1648-54.
3. Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002, 73:901-6.
4. Mazuelos F, Abril J, Zaragoza C. Cardiovascular morbidity and obesity in adult liver transplant recipients. Transplant Proc 2003, 35:1909-10.
5. Ciccarelli O, Kaczmarek B, Roggen F. Long-term medical complications and quality of life in adult recipients surviving 10 years or more after liver transplantation. Acta Gastroenterol Belg 2005, 68:323-30.
6. Pruthi J, Medkiff KA, Esrason KT. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 2001, 7:811-15.
7. Kashyap R, Jain A, Reyes J. Causes of death after liver transplantation in 4000 consecutive patients: 2 to 19 year follow-up. Transplant Proc 2001, 33:1482-3.
8. Gonwa A. Hypertension and renal dysfunction in long-term liver transplant recipients. Liver Transpl 2001, 7:S22-26.
9. Hong JC, Kahan BD. Immunosuppressive agents in organ transplantation: past, present, and future. Semin Nephrol 2000, 20:108-25.
10. Canzanello VJ, Schwartz L, Taler SJ. Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506). Liver Transpl Surg 1997, 3:1-9.
11. Guckelberger O, Bechstein WO, Neuhaus R. Cardiovascular risk factors in long-term follow-up after orthotopic liver transplantation. Clin Transplant 1997, 11:60-5.
12. Fernandez-Miranda C, Sanz M, dela Calle A. Cardiovascular risk factors in 116 patients 5 years or more after liver transplantation. Transpl Int 2002, 15:556-62.
13. Jain AB, Kashyap R, Rakela J, Starzl TE, Fung JJ. Primary adult liver transplantation under tacrolimus: more than 90 months actual follow-up survival and adverse events. Liver Transpl Surg 1999, 5:144-50.
14. Rabkin JM, Rosen HR, Corless CL, Olyaei AJ. Tacrolimus is associated with a lower incidence of cardiovascular complications in liver transplant recipients. Transplant Proc 2002, 34:1557-8.
15. Avdonin PV, Cottet-Maire F, Afanasjeva GV, Loktionova SA, Lhote P, Ruegg UT. Cyclosporine A up-regulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells. Kidney Int 1999, 55:2407-14.
16. Canzanello VJ, Textor SC, Taler SJ. Renal sodium handling with cyclosporine A and FK506 after orthotopic liver transplantation. J Am Soc Nephrol 1995, 5:1910-7.
17. Oriji GK, Keiser HR. Role of nitric oxide in cyclosporine A-induced hypertension. Hypertension 1998, 32:849-55.
18. Textor SC, Burnett JC, Romero JC. Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation. Kidney Int 1995, 47:1426-33.
19. Scherrer U, Vissing SF, Morgan BJ. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med 1990, 323:693-99.
20. Saruta T. Mechanism of glucocorticoid-induced hypertension. Hypertens Res 1996, 19:1-8.
21. Mitchell BM, Webb RC. Impaired vasodilatation and nitric oxide synthase activity in glucocorticoid-induced hypertension. Biol Res Nurs 2002, 4:16-21.
22. Guckelberger O. Long-term medical comorbidities and their management: hypertension/cardiovascular disease. Liver Transpl 2009, 15((Suppl. 2)):S75-8.
23. Obarzanek E, Proschan MA, Vollmer WM. Individual blood pressure responses to changes in salt intake: Results from the DASH sodium trial. Hypertension 2003, 42:459-67.
24. Miller ER, Erlinger TP, Young DR. Results of the diet, exercise, and weight loss intervention trial (DEW-IT). Hypertension 2002, 40:612-18.
25. Textor SC, Taler SJ, Canzanello VJ, Schwartz L, Augustine JE. Posttransplantation hypertension related to calcineurin inhibitors. Liver Transpl 2000, 6:521-30.
26. Textor SC, Canzanello VJ, Taler SJ. Cyclosporine-induced hypertension after transplantation. Mayo Clin Proc 1994, 69:1182-93.
27. Galioto A, Semplicini A, Zanus G. Nifedipine versus carvedilol in the treatment of de novo arterial hypertension after liver transplantation: results of a controlled clinical trial. Liver Transpl 2008, 14:1020-28.
28. Neal DA, Brown MJ, Wilkinson IB, Byrne CD, Alexander GJ. Hemodynamic effects of amlodipine, bisoprolol, and lisinopril in hypertensive patients after liver transplantation. Transplantation 2004, 77:748-50.
29. Lee DB. Cyclosporine and the renin-angiotensin axis. Kidney Int 1997, 52:248-60.
30. Branten AJ, Hilbrands LB, van Hamersvelt HW, Koene RA, Huysmans FT. Renal and systemic effects of atenolol and tertatolol in renal transplant recipients on cyclosporine A. Nephrol Dial Transplant 1998, 13:423-6.
31. Sennesael J, Lamote J, Violet I, Tasse S, Verbeelen D. Comparison of perindopril and amlodipine in cyclosporine-treated renal allograft recipients. Hypertension 1995, 26:436-44.
32. Lucey MR, Abdelmalek MF, Gagliardi R. A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. Am J Transplant 2005, 5:1111-9.
33. Neal DA, Gimson AE, Gibbs P, Alexander GJ. Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight. Liver Transpl 2001, 7:533-9.
34. Copley JB, Staffeld C, Lindberg J. Cyclosporine to tacrolimus: effect on hypertension and lipid profiles in renal allografts. Transplant Proc 1998, 30:1254-6.
35. Moreno JM, Rubio E, Gomez A. Effectiveness and safety of mycophenolate mofetil as monotherapy in liver transplantation. Transplant Proc 2003, 35:1874-6.
36. Herrero JI, Quiroga J, Sangro B. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. Liver Transpl Surg 1999, 5:414-20.
37. Kreis H, Oberbauer R, Campistol JM. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004, 15:809-17.
38. Stegall MD, Everson GT, Schroter G. Prednisolone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolaemia without causing graft loss. Hepatology 1997, 25:173-7.
39. Lladó L, Xiol X, Figueras J. Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study. J Hepatol 2006, 44:710-16.
40. Trotter JF, Wachs ME, Trouillot TE. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus. Liver Transpl 2001, 7:401-8.
41. Neff GW, Montalbanoa M, Tzakisa AG. Ten years of sirolimus therapy in orthotopic liver transplant recipients. Transplantation Proceedings 2003, 35((Suppl. 1)):S209-16.
42. Morrisett JD, Abdel-Fattah G, Hoogeveen R. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 2002, 43:1170-80.
43. Mells G, Neuberger J. Reducing the risks of cardiovascular disease in liver allograft recipients. Transplantation 2007, 83:1141-50.
44. Ballantyne CM, Radovancevic B, Farmer JA. Hyperlipidaemia after heart transplantation: report of a 6-year experience with treatment recommendations. J Am Coll Cardiol 1992, 19:1315-21.
45. Taylor PJ, Kubler PA, Lynch SV, Allen J, Butler M, Pillans PI. Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients. Ann Pharmacother 2004, 38:205-8.
46. Imigawa DK, Dawson S, Holt CD. Hyperlipidaemia after liver transplantation: natural history and treatment with the hydroxylmethylglutaryl-coenzyme A reductase inhibitor pravastatin. Transplantation 1996, 62:934-42.
47. Baigent C, Keech A, Kearney PM. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-78.
48. Chan TM, Cheng IK, Tam SC. Hyperlipidemia after renal transplantation: treatment with gemfibrozil. Nephron 1994, 67:317-21.
49. Pflugfelder PW, Huff M, Oskalns R, Rudas L, Kostuk WJ. Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial. J Heart Lung Transplant 1995, 14:613-22.
50. Hanes DS, Nicholson PG, Raval DD, Hooper FL, Behrens MT, Weir MR. A crossover comparison of the efficacy and safety of lovastatin and gemfibrozil in the treatment of hyperlipidemic organ transplant recipients. Am J Ther 1997, 4:85-91.
51. Hidalgo L, Zambrana JL, Blanco-Molina A. Lovastatin versus bezafibrate for hyperlipemia treatment after heart transplantation. J Heart Lung Transplant 1995, 14:461-7.
52. Vergoulas G, Miserlis G, Solonaki F. Combined treatment of hypercholesterolaemia of renal transplant allograft recipients with fluvastatin and gemfibrozil. Transpl Int 2000, 13:S64-67.
53. Lal SM, Hewett JE, Petroski GF, Van Stone JC, Ross G. Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial. Am J Kidney Dis 1995, 25:616-22.
54. Almutairi F, Peterson TC, Molinari M, Walsh MJ, Alwayn I, Peltekian KM. Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia. Liver Transpl 2009, 15:504-8.
55. Kohnle M, Pietruck F, Kribben A, Philipp T, Heemann U, Witzke O. Ezetimibe for the treatment of uncontrolled hypercholesterolaemia in patients with high dose statin therapy after renal transplantation. Am J Transpl 2006, 6:205-8.
56. Asberg A, Hartmann A, Fjeldså E, Bergan S, Holdaas H. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transpl 2001, 1:382-6.
57. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001, 35:1096-107.
58. Charlton M. Obesity, hyperlipidemia, and metabolic syndrome. Liver Transpl 2009, 15:S83-9.
59. Kobashigawa JA, Kasiske BL. Hyperlipidaemia in solid organ transplantation. Transplantation 1997, 63:331-8.
60. Pisanti N, Stanziale P, Imperatore P. Lack of effect of gemfibrozil on cyclosporine blood concentrations in kidney-transplanted patients. Am J Nephrol 1998, 18:199-203.
61. DeLorgeril M, Boissonnat P, Bizollon CA. Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate. Eur J Clin Pharmacol 1992, 43:161-5.
62. Roy A, Kneteman N, Lilly L. Tacrolimus as intervention in the treatment of hyperlipidemia after liver transplant. Transplantation 2006, 82:494-500.
63. Tueche SG. Diabetes mellitus after liver transplant new etiologic clues and cornerstones for understanding. Transplant Proc 2003, 35:1466-8.
64. Baid S, Cosimi AB, Farrell ML. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001, 72:1066-72.
65. Davidson J, Wilkinson A, Dantal J. New onset diabetes after transplantation: 2003 International Consensus Guidelines. Transplantation 2003, 75:SS3-24.
66. Bodziak KA, Hricik DE. New-onset diabetes mellitus after solid organ transplantation. Transpl Int 2009, 22:519-30.
67. Hashimoto M, Sugawara Y, Tamura S. Bloodstream infection after living donor liver transplantation. Scand J Infect Dis 2008, 40:509-16.
68. Yoo HY, Thuluvath PJ. The effect of insulin-dependent diabetes mellitus on outcome of liver transplantation. Transplantation 2002, 74:1007-12.
69. John PR, Thuluvath PJ. Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. Liver Transpl 2002, 8:708-13.
70. Trail KC, McCashland TM, Larsen JL. Morbidity in patients with posttransplant diabetes mellitus following orthotopic liver transplantation. Liver Transpl Surg 1996, 2:276-83.
71. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-89.
72. Navasa M, Bustamante J, Marroni C. Diabetes mellitus after liver transplantation: prevalence and predictive factors. J Hepatol 1996, 25:64-71.
73. Saab S, Shpaner A, Zhao Y. Prevalence and risk factors for diabetes mellitus in moderate term survivors of liver transplantation. Am J Transplant 2006, 6:1890-5.
74. Driscoll CJ, Cashion AK, Hathaway DK. Posttransplant diabetes mellitus in liver transplant recipients. Prog Transplant 2006, 16:110-6.
75. AlDosary AA, Ramji AS, Elliott TG. Postliver transplant diabetes mellitus: an association with hepatitis C. Liver Transplant 2002, 8:356-61.
76. Delgado-Borrego A, Casson D, Schoenfeld D. Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation 2004, 77:703-10.
77. Masini M, Campani D, Boggi U. Hepatitis C virus infection and human pancreatic beta-cell dysfunction. Diabetes Care 2005, 28:940-1.
78. Hjelmesaeth J, Hartmann A, Kofstad J. Glucose intolerance after renal transplantation depends on prednisolone dose and recipient age. Transplantation 1997, 64:979-83.
79. Short KR, Bigelow ML, Nair KS. Short-term prednisone use antagonizes insulin's anabolic effect on muscle protein and glucose metabolism in young health people. Am J Physiol Endocrinol Metab 2009, 297:E1260-8.
80. Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving Calcineurin inihibitors: a systemic review and meta-analysis. Am J Transplant 2004, 4:583-95.
81. Sánchez-Pérez B, Aranda Narváez JM, Santoyo Santoyo J. Influence of immunosuppression and effect of hepatitis C virus on new onset of diabetes mellitus in liver transplant recipients. Transplant Proc 2008, 40:2994-6.
82. Drachenberg CB, Klassen DK, Weir MR. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999, 68:396-402.
83. Marchetti P. New-onset diabetes after liver transplantation: from pathogenesis to management. Liver Transpl 2005, 11:612-20.
84. Villanueva G, Baldwin D. Rosiglitazone therapy of posttransplant diabetes mellitus. Transplantation 2005, 80:1402-5.
85. Luther P, Baldwin D. Pioglitazone in the management of diabetes mellitus after transplantation. Am J Transplant 2004, 4:2135-8.
86. Emre S, Genyk Y, Schluger LK. Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients. Transpl Int 2000, 13:73-8.
87. Dumortier J, Bernard S, Bouffard Y, Boillot O. Conversion from tacrolimus to cyclosporine in liver transplanted patients with diabetes mellitus. Liver Transpl 2006, 12:659-64.
88. Herrero JI, Quiroga J, Sangro B. Conversion from calcineurin inhibitors to mycophenolate mofetil in liver transplant recipients with diabetes mellitus. Transplant Proc 2003, 35:1877-9.
89. Schaeffer DF, Yoshida EM, Buczkowski AK. Surgical morbidity in severely obese liver transplant recipients - a single Canadian Centre Experience. Ann Hepatol 2009, 8:38-40.
90. Sawyer RG, Pelletier J, Pruett TL. Increased early morbidity and mortality with acceptable long-term function in severely obese patients undergoing liver transplantation. Clin Transplant 1999, 13:126-30.
91. Nair S, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002, 35:105-9.
92. Palmer M, Schaffner F, Thung SN. Excessive weight gain after liver transplantation. Transplantation 1991, 51:797-800.
93. Richards J, Gunson B, Johnson J, Neuberger J. Weight gain and obesity after liver transplantation. Transpl Int 2005, 18:461-6.
94. Nair S, Cohen DB, Cohen MS, Tan H, Maley W, Thuluvath PJ. Postoperative morbidity, mortality, costs, and long-term survival in severely obese patients undergoing liver transplantation. Am J Gastroenterol 2001, 96:842-5.
95. Everhart JE, Lombardero M, Lake JR, Wiesner RH, Zetterman RK, Hoofnagle JH. Weight change and obesity after liver transplantation: incidence and risk factors. Liver Transpl Surg 1998, 4:285-96.
96. T D Correia MI, Rego LO, Lima AS. Post-liver transplant obesity and diabetes. Curr Opin Clin Nutr Metab Care 2003, 6:457-60.
97. Cassiman D, Roelants M, Vandenplas G. Orlistat treatment is safe in overweight and obese liver transplant recipients: a prospective, open label trial. Transpl Int 2006, 19:1000-5.
98. Everson GT, Trouillot T, Wachs M. Early steroid withdrawal in liver transplantation is safe and beneficial. Liver Transpl Surg 1999, 5:S48-57.